Core Viewpoint - Gain Therapeutics, Inc. has made significant advancements in the development of its lead candidate GT-02287 for treating Parkinson's disease, showing promising results in clinical studies and financial performance improvements [2][3][5]. Pipeline Updates - The company presented initial data from the Phase 1b clinical study of GT-02287, demonstrating its disease-modifying potential for Parkinson's disease at various scientific conferences [4]. - As of March 2026, 14 out of 16 participants in the Phase 1b nine-month extension study completed 150 days of treatment, with stable MDS-UPDRS scores observed [4]. - In participants with elevated glucosylsphingosine (GluSph) levels, an average decrease of 81% was noted after 90 days of treatment with GT-02287 [4]. - The company introduced GT-04686, a novel glucocerebrosidase (GCase) allosteric modulator, which is ready for IND-enabling studies for Parkinson's disease and other neurological disorders [4]. Financial Results - Research and development (R&D) expenses decreased by $0.6 million to $10.2 million for the year ended December 31, 2025, compared to $10.8 million in 2024, primarily due to pipeline cost optimization [5]. - General and administrative (G&A) expenses decreased by $1.1 million to $8.5 million for the year ended December 31, 2025, from $9.6 million in 2024, attributed to lower stock-based compensation and legal fees [6]. - The net loss for the year ended December 31, 2025, was $20.2 million, or $0.61 per share, compared to a net loss of $20.4 million, or $0.89 per share, for the previous year [7]. Corporate Updates - Gain Therapeutics has received funding support for its lead program in Parkinson's disease from The Michael J. Fox Foundation and other organizations [14]. - The company is preparing for Phase 2 clinical development of GT-02287 in the United States, with IND clearance expected in Q2 2026 [12]. - The Phase 2 clinical trial for GT-02287 is anticipated to begin in Q3 2026, with results from the Phase 1b study expected in Q4 2026 [12].

Core Insights - Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation allosteric small molecule therapies [3] - The company will participate in the 38th Annual ROTH Conference from March 22-24, 2026, with a fireside chat scheduled for March 23, 2026, at 11:30 a.m. PT [1][2] Company Overview - Gain Therapeutics is leading the discovery and development of allosteric therapies, with its lead drug candidate GT-02287 currently in a Phase 1b clinical trial for Parkinson's disease [3] - The company is also exploring GT-02287's potential in treating Gaucher's disease, dementia with Lewy bodies, and Alzheimer's disease [3] - Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors [3] Technology and Approach - Gain's unique approach involves discovering novel allosteric small molecule modulators that can restore or disrupt protein function [4] - The company utilizes its advanced Magellan™ platform to accelerate drug discovery and develop disease-modifying treatments for challenging disorders, including neurodegenerative diseases and rare genetic disorders [4]

Core Insights - Gain Therapeutics, Inc. presented new clinical and biomarker data for GT-02287 at the AD/PD 2026 conference, supporting its potential as a disease-modifying treatment for Parkinson's disease [1][2][6] Group 1: Clinical Study Results - The Phase 1b study of GT-02287 showed a reduction in cerebrospinal fluid (CSF) glucosylsphingosine (GluSph) levels after 90 days of treatment, indicating a positive response in participants with elevated baseline GluSph [3][4] - MDS-UPDRS scores remained stable over 150 days of dosing, with participants having high baseline GluSph showing a 6.7-point improvement compared to those with low baseline levels [4][6] - The study's Data Monitoring Committee recommended continuing the trial without changes, reflecting the treatment's safety and tolerability [2] Group 2: Biomarker Analysis - Higher levels of DOPA decarboxylase (DDC) were observed at baseline, which decreased after 90 days of GT-02287 treatment, suggesting a positive impact on dopaminergic neuron function [5][6] - The correlation between decreased GluSph, reduced DDC levels, and improved MDS-UPDRS scores supports the drug's mechanism of action targeting the underlying biology of Parkinson's disease [6] Group 3: Future Development - Gain Therapeutics is advancing a novel chemical series of allosteric glucocerebrosidase (GCase) modulators, led by GT-04686, which is ready for IND-enabling studies for Parkinson's disease and other neurological disorders [1][7][8] - The company aims to shift the treatment paradigm from symptomatic relief to disease modification, with ongoing studies expected to yield further data [6][14]

Core Insights - Gain Therapeutics, Inc. is advancing its lead drug candidate GT-02287 for the treatment of Parkinson's disease, with an interim analysis of the Phase 1b clinical study to be presented at the AD/PD 2026 conference [1][2] - The company is on track to initiate a Phase 2 clinical trial of GT-02287 in the third quarter of 2026 after submitting additional preclinical data requested by the FDA [1][4] Clinical Development - The Phase 1b study of GT-02287 has shown promising results, including central nervous system target engagement and early signs of clinical improvement in patients [2][10] - The primary endpoint of the ongoing Phase 1b trial is to evaluate the safety and tolerability of GT-02287 after three months of dosing in participants with Parkinson's disease [9] - An extension of the Phase 1b study allows participants to continue treatment for up to 12 months, with completion expected in September 2026 [6][9] Presentation Details - Dr. Jonas Hannestad will present findings from the Phase 1b study, highlighting CNS target engagement and beneficial effects on downstream pathway abnormalities [2] - A poster presentation will feature a novel glucocerebrosidase (GCase) modulator distinct from GT-02287, showing promising preclinical data [3] Regulatory Update - Gain Therapeutics submitted an Investigational New Drug (IND) application to conduct a placebo-controlled Phase 2 clinical trial in the U.S. and is awaiting FDA feedback [4][6] - The company has been in close communication with the FDA and anticipates starting the Phase 2 trial as planned [4][6] Mechanism of Action - GT-02287 is an allosteric enzyme modulator that aims to restore the function of the lysosomal enzyme glucocerebrosidase (GCase), which is often impaired in Parkinson's disease [6][12] - Preclinical studies indicate that GT-02287 can restore GCase function, reduce neuroinflammation, and improve motor function in animal models of Parkinson's disease [7][10] Funding and Support - Gain Therapeutics has received funding support from The Michael J. Fox Foundation and other organizations to advance its research and development efforts [11]

Core Insights - Gain Therapeutics, Inc. is participating in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026, where the management team will engage in a fireside chat and one-on-one meetings [1][2] Company Overview - Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing next-generation allosteric therapies [3] - The lead drug candidate, GT-02287, is currently in a Phase 1b clinical trial for treating Parkinson's disease, with potential applications in Gaucher's disease, dementia with Lewy bodies, and Alzheimer's disease [3] - The company has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors [3] Technology and Approach - Gain Therapeutics employs a unique approach to discover novel allosteric small molecule modulators that can restore or disrupt protein function [4] - Utilizing the advanced Magellan™ platform, the company aims to accelerate drug discovery and develop disease-modifying treatments for challenging disorders, including neurodegenerative diseases and rare genetic disorders [4]

Core Viewpoint - Gain Therapeutics, Inc. is actively participating in key healthcare conferences to showcase its advancements in allosteric small molecule therapies, particularly focusing on its lead drug candidate GT-02287 for Parkinson's disease [1][2]. Conference Participation - Gain Therapeutics will attend the 44th Annual J.P. Morgan Healthcare Conference and other related events, including the Sachs Neuroscience Innovation Forum on January 11, 2026, and the Demy-Colton/Informa Biotech Showcase from January 12-14, 2026 [1][3]. - The company will conduct presentations and one-on-one meetings with management during these events, providing opportunities for investors and stakeholders to engage directly [3][4]. Drug Development - GT-02287 is in clinical development for treating Parkinson's disease, targeting both patients with and without a GBA1 mutation [5][8]. - The drug functions as an allosteric enzyme modulator, aiming to restore the function of the glucocerebrosidase enzyme, which is often impaired due to genetic mutations or age-related stress [5]. - In preclinical models, GT-02287 has shown promising results, including restoration of enzymatic function and reduction of neurodegeneration biomarkers [5][6]. Clinical Trials - GT-02287 is currently undergoing a Phase 1b clinical trial across seven sites in Australia, focusing on safety and tolerability over a three-month period [6]. - An extension of the Phase 1b study allows participants to continue treatment for up to 12 months, indicating a commitment to long-term evaluation of the drug's effects [6]. Funding and Support - The development of GT-02287 has received funding from notable organizations, including The Michael J. Fox Foundation and the Eurostars-2 program, highlighting the drug's potential and the support it has garnered [7]. Company Overview - Gain Therapeutics is a clinical-stage biotechnology company specializing in the discovery and development of next-generation allosteric therapies, with a focus on neurodegenerative diseases and other challenging disorders [8][10]. - The company employs its proprietary Magellan™ platform to accelerate drug discovery and develop novel treatments for various conditions, including lysosomal storage disorders and solid tumors [10].

Core Insights - Gain Therapeutics, Inc. has provided additional biomarker and clinical data from the Phase 1b clinical study of GT-02287, indicating its potential as a disease-modifying therapy for Parkinson's disease [1] Group 1: Clinical Data and Results - In participants with elevated baseline levels of glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), GluSph decreased by an average of 81% after 90 days of treatment with GT-02287, suggesting increased GCase activity in the brain [2] - Out of 19 patients who completed Part 1 of the study, 15 patients showed an average improvement of 2.20 points in the sum of MDS-UPDRS Part II and Part III scores after treatment [3] - The study observed stabilization in MDS-UPDRS scores and anecdotal improvements in specific functional areas such as balance, gait, and sense of smell after 90 days of dosing with GT-02287 [4] Group 2: Drug Candidate Information - GT-02287 is an orally administered, brain-penetrant small molecule that acts as an allosteric enzyme modulator, restoring the function of the lysosomal enzyme glucocerebrosidase (GCase) [6] - Preclinical models have shown that GT-02287 can restore GCase enzymatic function and reduce various pathologies associated with Parkinson's disease [6][7] - The drug is currently being evaluated in a Phase 1b clinical trial, with the primary endpoint focused on safety and tolerability after three months of dosing [9] Group 3: Future Developments and Support - Gain Therapeutics has received funding support from The Michael J. Fox Foundation for Parkinson's Research and other organizations to advance the development of GT-02287 [10] - The company is hosting a virtual event to discuss the results of the Phase 1b clinical study and engage with key opinion leaders in the field [5]

Core Viewpoint - Gain Therapeutics, Inc. is advancing its lead drug candidate GT-02287 for the treatment of Parkinson's disease, with a focus on its disease-modifying potential and biomarker data from a Phase 1b clinical study [1][2]. Company Overview - Gain Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of next-generation allosteric therapies [10]. - The company is currently evaluating GT-02287 in a Phase 1b clinical trial for Parkinson's disease, targeting patients with or without a GBA1 mutation [10]. Drug Candidate Details - GT-02287 is an orally administered, brain-penetrant small molecule that acts as an allosteric enzyme modulator, restoring the function of the lysosomal enzyme glucocerebrosidase (GCase) [5]. - Preclinical studies have shown that GT-02287 can restore GCase enzymatic function and reduce various pathologies associated with Parkinson's disease, including neuroinflammation and neuronal death [5][6]. - The drug has demonstrated a disease-modifying effect in preclinical models, suggesting potential to slow or stop the progression of Parkinson's disease [6]. Clinical Study Insights - The Phase 1 study of GT-02287 in healthy volunteers indicated favorable safety and tolerability, with target engagement reflected in increased GCase activity [7]. - The ongoing Phase 1b clinical trial has enrolled participants across seven sites in Australia, focusing on the safety and tolerability of GT-02287 after three months of dosing [8]. - An extension of the Phase 1b study allows participants to continue treatment for up to 12 months [8]. Funding and Support - Gain Therapeutics has received funding support for its lead program from The Michael J. Fox Foundation for Parkinson's Research and The Silverstein Foundation for Parkinson's with GBA, among others [9].

Core Insights - Gain Therapeutics, Inc. has reported a significant reduction in glucosylsphingosine (GluSph) levels in cerebrospinal fluid (CSF) of Parkinson's disease (PD) patients after treatment with their drug candidate GT-02287, indicating increased GCase activity in the brain, which may influence PD progression [1][2][3] Group 1: Study Results - The Phase 1b study of GT-02287 showed that all participants with elevated GluSph levels experienced substantial decreases towards levels seen in healthy individuals after 90 days of treatment [2] - The study enrolled 21 participants, with 19 completing the 90-day dosing period, and 15 (79%) opting to continue into a nine-month extension [4] - The data monitoring committee has recommended the continuation of the Phase 1b study with no changes, confirming the treatment's tolerability [5] Group 2: Future Plans and Events - A KOL event is scheduled for January 6, 2026, to discuss the results of the study and emerging biomarker data [6] - The company plans to present longer follow-up data at the AD/PD™ conference in March 2026, focusing on the effects of GT-02287 on MDS-UPDRS scores [3] Group 3: Drug Candidate Overview - GT-02287 is an orally administered, brain-penetrant small molecule that acts as an allosteric enzyme modulator, aimed at restoring the function of the lysosomal enzyme glucocerebrosidase (GCase) [7][8] - Preclinical studies have shown that GT-02287 can restore GCase function, reduce ER stress, and improve motor function in models of both GBA1-PD and idiopathic PD [9][10] Group 4: Funding and Support - Gain Therapeutics has received funding support from The Michael J. Fox Foundation for Parkinson's Research, The Silverstein Foundation, and the Eurostars-2 joint program [12]

Core Insights - Gain Therapeutics, Inc. announced promising preclinical data for its lead drug candidate GT-02287, which shows potential as a disease-modifying therapy for Parkinson's disease (PD) by enhancing mitochondrial and lysosomal health [1][2][7] Preclinical Data - GT-02287 demonstrated a reduction in mitochondrial stress and improved neuronal survival in rat dopaminergic neurons treated with MPP+, a mitochondrial toxin [3] - In a mouse PD model, GT-02287 decreased staining for MIRO1, indicating improved mitochondrial health [4] - The drug facilitated the trafficking of glucocerebrosidase (GCase) to mitochondria, enhancing mitochondrial function in patient-derived fibroblasts with GBA1 mutations [5][6] Mechanism of Action - The drug acts throughout the disease cascade resulting from dysfunctional GCase, contributing to neuroprotection by restoring GCase function and reducing neuroinflammation and neuronal death [2][6][7] - GT-02287's effects on mitochondrial health were highlighted as a significant aspect of its mechanism, addressing previously open questions in PD research [2][4] Clinical Development - GT-02287 is currently in a Phase 1b clinical trial for PD, with early observations suggesting disease-modifying effects consistent with preclinical findings [9] - The trial aims to evaluate safety and tolerability after 3 months of dosing, with an extension allowing treatment for up to 12 months [9] Funding and Support - The development of GT-02287 has received funding from notable organizations, including The Michael J. Fox Foundation and the Eurostars-2 joint program [10]